Inborn errors of immunity: a structured model for paediatric-to-adult transition of care

Adele Civino1, Federico Diomeda1, Concetta D'Orio2

  • 1Pediatric Rheumatology and Immunology Unit, 'Vito Fazzi' Hospital, Lecce, Italy.

Insights

Transitioning patients with inborn errors of immunity (IEI) to adult care requires a structured protocol. This multidisciplinary approach ensures continuity of care, adherence, and better long-term outcomes for these complex patients.

Area of Science:

  • Immunology
  • Healthcare Management
  • Paediatric Medicine

Background:

  • Inborn errors of immunity (IEI) patients face critical care gaps during transition from pediatric to adult services.
  • Lack of standardized guidelines leads to adverse outcomes like non-adherence and increased healthcare utilization.
  • Growing IEI adult population necessitates improved transition strategies.

Purpose of the Study:

  • To propose a structured, multidisciplinary transition protocol for IEI patients.
  • To enhance therapeutic adherence, continuity of care, and patient well-being during transition.
  • To provide a framework for managing IEI patients into adulthood.

Main Methods:

  • Practice-informed narrative review integrating literature, expert consensus, and clinical experience.
  • Early patient identification (age 14) and a minimum 3-year overlap with multidisciplinary team involvement.
  • Standardized documentation (clinical dossier, transition report) and outcome indicators (infection rates, quality of life).

Main Results:

  • A proposed model emphasizes early identification, multidisciplinary team collaboration, and clear documentation.
  • Addresses immunoglobulin replacement therapy options and patient empowerment.
  • Highlights adaptability to various healthcare settings, despite resource needs.

Conclusions:

  • A structured, multidisciplinary protocol is crucial for successful IEI patient transition to adult care.
  • Standardized strategies can bridge care gaps, reduce discontinuity, and improve long-term management.
  • Further research is needed to prospectively validate the protocol's impact on clinical outcomes.

Related Concept Videos

Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Introduction to Innate and Adaptive Immunity01:21

Introduction to Innate and Adaptive Immunity

The human immune system is a complex defense mechanism that protects the body from harmful pathogens and foreign substances. It comprises two crucial components: innate and adaptive immunity.
Innate immunity is the body's natural, nonspecific defense system that acts quickly to protect against pathogens. It incorporates physical barriers like skin and mucous membranes and cellular elements such as phagocytes and natural killer cells. This part of our immune system provides an immediate,...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...